Monica Bianchini, PharmD, MPH

PharmD, MPH - @UWMadPharmacy ➡️

PGY1/PGY2 Infectious Diseases - @HFHPharmRes ➡️

PhD student, Pharmaceutical Outcomes Research - @CUAnschutz

[Christian Gill @c_gill11]

Congrats ⁦@mbianchini12⁩ excited to read this! Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections https://t.co/vsw2uVkDWt

[Athena Hobbs @AthenaLVHobbs]

Great new article by @mbianchini12, @PharmerMeg, and Jonathan Campbell about cost effectiveness of new BL/BLI vs. Colistin. They did a great job capturing indirect cost of AKI and QALYs! https://t.co/JUQB4gyjmE

[Monica Bianchini, PharmD, MPH @mbianchini12]

My dad advocated for himself at the pharmacy to get the PPSV23 vaccine today! We've talked a lot about vaccines. He made me proud with that one. #VaccinesWork

[Monica Bianchini, PharmD, MPH @mbianchini12]

Today is a great day to ask your Senators to co-sponsor the PASTEUR Act! This AMR bill encourages sustainable antimicrobial development and supports antimicrobial stewardship. Take action! @CoryGardner @MichaelBennet

https://t.co/PaSnykWMEN

[Sen. Bernie Sanders @SenSanders]

"Out of an abundance of caution," we should expand Medicare to cover everyone in America.

[Monica Bianchini, PharmD, MPH @mbianchini12]

Rescued my dog off the street in Detroit almost 2 years ago. Un-spayed, underweight, chronic ear infections, heartworm+.

Today, we got results that she is HEARTWORM NEGATIVE! Treatment can be brutal, especially for older dogs, so I am beaming. Rawhides for Hazelnut all week!!

[HealthEconomics.com | A Scientist.com Company @www_healthecon]

#Remdesiver cost-effectiveness model explained by Jonathan Campbell PhD

[Monica Bianchini, PharmD, MPH @mbianchini12]

So happy this recording is available! Great talks about all my favorite things: CEA, global health, and infectious diseases (+pandemics)

[Peter Neumann @PeterNeumann11]

Take-away from our recent @TuftsCEVR webinar: there are many disease areas with lots of DALYs, few CEAs. We need more CEAs to support key #UHC priorities.
Thanks @dollendorf; @glassmanamanda, @Maryam_huda67 for remarks!
ICYMI, the recording is here: https://t.co/ZjB94vu9ga @cgd

[MAD-ID The Antimicrobial Stewardship Meeting®️ @MAD_ID_ASP]

While the 2020 MAD-ID Annual Meeting, originally scheduled for late May, was cancelled, you can still check out the accepted abtracts here https://t.co/T9NacbxtRA. Lots of great research projects! @JayCdoesID @Sara_Alosaimy @TayMorrisette @mbianchini12 @EudyJL #IDTwitter

[(((Charles Fishman))) 💧 @cfishman]

A single coronavirus update snapshot.

Florida.

FL got a lot of praise for how it handled nursing home cases (very well).

Florida pushed opening amid sneering from people who didn't understand its case spread.

Now?

Last 4 days: Most new cases of any 4-days in the pandemic.

[Monica Bianchini, PharmD, MPH @mbianchini12]

One of the best parts of an overnight shift is walking laps around the hospital at 5am so I can watch the sunrise 🌞

[Andrew Althouse @ADAlthousePhD]

The NEJM compassionate-use remdesivir data was always sort of a "passing curiosity while we await trial data" but it's disappointing that the analysis was done wrong.

But, it offers an opportunity for a teachable moment about "time-to-event" analysis of non-mortality outcomes.

[Monica Bianchini, PharmD, MPH @mbianchini12]

@IDPharmProf @MJSculpher And last, the official summary from @MJSculpher because he can definitely say it better than I!

**dissertation ideas brewing**

[Monica Bianchini, PharmD, MPH @mbianchini12]

Do you ever have those moments as a learner where you think, "THIS is my jam!!"?

🙋🏻‍♀️Me during #ISPORAnnual session "identifying and evidencing the value of novel antibiotics - are health outcomes enough?"

THANK YOU to Monica Schneider, @MJSculpher and Silas Holland !

[Monica Bianchini, PharmD, MPH @mbianchini12]

@IDPharmProf @MJSculpher Also really loved this one showing the spectrum of value attributes & how hard these can be to measure!

[Monica Bianchini, PharmD, MPH @mbianchini12]

@IDPharmProf @MJSculpher Take away: evaluating the value of antibiotics is HARD and needs some some novel approaches compared to other health technology assessment!

My favorite slide describing the various types of inputs that could/should be considered in economic evaluations of novel antibiotics:

[Peter Neumann @PeterNeumann11]

No easy answers for how to appropriately value & price #Remdesivir, but we offer thoughts in @Health_Affairs today on how to think about cost vs value-based pricing (& what to include in value calculations). https://t.co/Ao5U9lXh4t @TuftsCEVR @dollendorf @contirena1 @DusetzinaS

[Monica Bianchini, PharmD, MPH @mbianchini12]

You guys rock!!! @A_Morrison17 @rkenneypharmd @BugsOnDrugsMD

[SIDP @SIDPharm]

New multi-center quasi-experimental study published by multiple @SIDPharm members in CID evaluated impact of early short-course corticosteroids on clinical outcomes in n=213 patients w/ #COVID19

Full article here: https://t.co/H5W5d9x86b

[Dr Ellie Murray, ScD @EpiEllie]

There’s a new paper circulating today about “risk factors” for COVID19 which is getting misinterpreted in a pretty common way: applying conclusions about causation to results obtained via methods designed only for finding correlations.

It’s time for a #tweetorial!

[ICER @icer_review]

Following today's FDA emergency use authorization, ICER presents alternative pricing models for Remdesivir as a treatment for COVID-19: https://t.co/pG2dSurbcw